Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00680225 · ClinicalTrials.gov registry record · Phase 3

Lucentis as an Adjuvant Therapy With TTT-ICG Based in Choroidal Melanoma

A Phase 3 study, sponsored by New England Retina Associates.

Completed
Registry status
Phase 3
Development phase
10
Enrollment target

NCT00680225: Completed Phase 3 study, sponsored by New England Retina Associates.

NCT00680225 is a Phase 3 study that has completed, run by New England Retina Associates. The registered enrollment target is 10 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (99% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00680225, a Phase 3 study, has completed, sponsored by New England Retina Associates.

COMPLETED
Registry status
Phase 3
Development phase
10 participants
Enrollment target

Study Summary

To report preliminary results on safety and tolerability of intravitreal injection of Ranibizumab (Lucentis) combined with Transpupillary Thermotherapy (TTT)+ Indocyanine Green (ICG)-based photodynamic therapy (PDT) in the treatment of choroidal melanoma.

Interventions

  • DRUG Ranibizumab injection and TTT - ICG based

Trial Details

FieldValue
Enrollment Target 10 participants
Start Date 2007-09
Est. Completion 2012-07
Phase Phase 3
New England Retina Associates

3 total trials

What the finished NCT00680225 record still lists

NCT00680225 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 10 participants, a relatively small participant target, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (99% lower).

The record links to 0 conditions, and to 1 intervention - of which Ranibizumab injection and TTT - ICG based is the first listed.

NCT00680225 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT00680225 about?

NCT00680225 is a clinical study titled "Lucentis as an Adjuvant Therapy With TTT-ICG Based in Choroidal Melanoma". To report preliminary results on safety and tolerability of intravitreal injection of Ranibizumab (Lucentis) combined with Transpupillary Thermotherapy (TTT)+ Indocyanine Green (ICG)-based photodynamic therapy (PDT) in the treatment of choroidal melanoma.

What is the current status of trial NCT00680225?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 10 participants. The study started on 2007-09. Estimated completion is 2012-07.

What interventions are being tested in trial NCT00680225?

The interventions under investigation include: Ranibizumab injection and TTT - ICG based (DRUG).

Who is sponsoring clinical trial NCT00680225?

This trial is sponsored by New England Retina Associates, which has 3 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT00680225's enrollment target sits among peer trials

10 1989th of 2000 higher than 9 of 2,000 other Phase 3 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00623389 · 10 participants · NA

    Evaluation of an Advanced Lower Extremity Neuroprostheses

  • NCT01241864 · 10 participants · Phase 2

    Islet Transplantation in Type 1 Diabetic Kidney Allograft

  • NCT01293214 · 10 participants · NA

    Vascularized Composite Allotransplantation for Multiple Extremity Amputations

  • NCT01474148 · 10 participants · NA

    A Neuroprosthesis for Seated Posture and Balance

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00680225, the US trial registry maintained by the National Library of Medicine. NCT00680225 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.